REFERENCES
1. Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin 2023;73:17-48.
2. Rassy E, Parent P, Lefort F, Boussios S, Baciarello G, Pavlidis N. New rising entities in cancer of unknown primary: is there a real therapeutic benefit? Crit Rev Oncol Hematol 2020;147:102882.
3. Ronchi E, Pizzocaro G, Miodini P, Piva L, Salvioni R, Di Fronzo G. Steroid hormone receptors in normal and malignant human renal tissue: relationship with progestin therapy. J Steroid Biochem 1984;21:329-35.
4. Zheng R, Zhang S, Zeng H, et al. Cancer incidence and mortality in China, 2016. J Nat Cancer Center 2022;2:1-9.
5. Kramer PA. Letter: albumin microspheres as vehicles for achieving specificity in drug delivery. J Pharm Sci 1974;63:1646-7.
6. Nizioł J, Ossoliński K, Ossoliński T, et al. Surface-transfer mass spectrometry imaging of renal tissue on gold nanoparticle enhanced target. Anal Chem 2016;88:7365-71.
7. Zheng S, Zhang M, Bai H, et al. Preparation of AS1411 aptamer modified Mn-MoS2 QDs for targeted MR imaging and fluorescence labelling of renal cell carcinoma. Int J Nanomed 2019;14:9513-24.
8. Pal K, Madamsetty VS, Dutta SK, Mukhopadhyay D. Co-delivery of everolimus and vinorelbine via a tumor-targeted liposomal formulation inhibits tumor growth and metastasis in RCC. Int J Nanomed 2019;14:5109-23.
9. Wu R, Wang K, Gai Y, et al. Nanomedicine for renal cell carcinoma: imaging, treatment and beyond. J Nanobiotechnol 2023;21:3.
10. Pontes O, Oliveira-Pinto S, Baltazar F, Costa M. Renal cell carcinoma therapy: current and new drug candidates. Drug Discov Today 2022;27:304-14.
11. Chiu IJ, Hsu YH, Chang JS, Yang JC, Chiu HW, Lin YF. Lactotransferrin downregulation drives the metastatic progression in clear cell renal cell carcinoma. Cancers 2020;12:847.
12. Zheng JQ, Lin CH, Lee HH, et al. Lactotransferrin downregulation serves as a potential predictor for the therapeutic effectiveness of mTOR inhibitors in the metastatic clear cell renal cell carcinoma without PTEN mutation. Biomedicines 2021;9:1896.
13. Caldorera-Moore M, Vela Ramirez JE, Peppas NA. Transport and delivery of interferon-α through epithelial tight junctions via pH-responsive poly(methacrylic acid-grafted-ethylene glycol) nanoparticles. J Drug Target 2019;27:582-9.
14. Strand MS, Krasnick BA, Pan H, et al. Precision delivery of RAS-inhibiting siRNA to KRAS driven cancer via peptide-based nanoparticles. Oncotarget 2019;10:4761-75.
15. Liu X, Li C, Lv J, et al. Glucose and H2O2 Dual-responsive polymeric micelles for the self-regulated release of insulin. ACS Appl Bio Mater 2020;3:1598-606.
16. Brown JE, Royle KL, Gregory W, et al. Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial. Lancet Oncol 2023;24:213-27.
17. Hillen F, Griffioen AW. Tumour vascularization: sprouting angiogenesis and beyond. Cancer Metastasis Rev 2007;26:489-502.
18. Mcdonald PC, Dedhar S. Carbonic anhydrase IX (CAIX) as a mediator of hypoxia-induced stress response in cancer cells. Subcell Biochem 2014;75:255-69.
19. Krall N, Pretto F, Mattarella M, Müller C, Neri D. A 99mTc-labeled ligand of carbonic anhydrase IX selectively targets renal cell carcinoma in vivo. J Nucl Med 2016;57:943-9.
20. Liao SY, Aurelio ON, Jan K, Zavada J, Stanbridge EJ. Identification of the MN/CA9 protein as a reliable diagnostic biomarker of clear cell carcinoma of the kidney. Cancer Res 1997;57:2827-31.
21. Alsaab HO, Sau S, Alzhrani RM, et al. Tumor hypoxia directed multimodal nanotherapy for overcoming drug resistance in renal cell carcinoma and reprogramming macrophages. Biomaterials 2018;183:280-94.
22. Chen L, Wang Z, Xu Q, et al. The failure of DAC to induce OCT2 expression and its remission by hemoglobin-based nanocarriers under hypoxia in renal cell carcinoma. Theranostics 2020;10:3562-78.
23. Zeng X, Teng Y, Zhu C, et al. Combined ibuprofen-nanoconjugate micelles with E-selectin for effective sunitinib anticancer therapy. Int J Nanomed 2022;17:6031-46.
24. Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R. Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov 2021;20:101-24.
25. Sercombe L, Veerati T, Moheimani F, Wu SY, Sood AK, Hua S. Advances and challenges of liposome assisted drug delivery. Front Pharmacol 2015;6:286.
26. Heng DY. The next 10 years: challenges for the future and overcoming resistance to targeted therapies for renal cell carcinoma. Can Urol Assoc J 2016;10:S256-8.
27. Chen J, Gao P, Yuan S, et al. Oncolytic adenovirus complexes coated with lipids and calcium phosphate for cancer gene therapy. ACS Nano 2016;10:11548-60.
28. Santiago-Ortiz JL, Schaffer DV. Adeno-associated virus (AAV) vectors in cancer gene therapy. J Control Release 2016;240:287-301.
29. Kulkarni JA, Witzigmann D, Leung J, Tam YYC, Cullis PR. On the role of helper lipids in lipid nanoparticle formulations of siRNA. Nanoscale 2019;11:21733-9.
30. Cheng X, Lee RJ. The role of helper lipids in lipid nanoparticles (LNPs) designed for oligonucleotide delivery. Adv Drug Deliv Rev 2016;99:129-37.
31. Felgner PL, Gadek TR, Holm M, et al. Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. Proc Natl Acad Sci USA 1987;84:7413-7.
32. Mislick KA, Baldeschwieler JD. Evidence for the role of proteoglycans in cation-mediated gene transfer. Proc Natl Acad Sci USA 1996;93:12349-54.
33. Akita H, Ishiba R, Togashi R, et al. A neutral lipid envelope-type nanoparticle composed of a pH-activated and vitamin E-scaffold lipid-like material as a platform for a gene carrier targeting renal cell carcinoma. J Control Release 2015;200:97-105.
34. Hama S, Kogure K. Nanoparticles consisting of tocopheryl succinate are a novel drug-delivery system with multifaceted antitumor activity. Biol Pharm Bull 2014;37:196-200.
35. He X, Zhou S, Dolan M, et al. Immunization with short peptide particles reveals a functional CD8+ T-cell neoepitope in a murine renal carcinoma model. J Immunother Cancer 2021;9:e003101.
36. Sarfraz M, Afzal A, Yang T, et al. Development of dual drug loaded nanosized liposomal formulation by A reengineered ethanolic injection method and its pre-clinical pharmacokinetic studies. Pharmaceutics 2018;10:151.
37. Poste G, Papahadjopoulos D, Vail WJ. Lipid vesicles as carriers for introducing biologically active materials into cells. Methods Cell Biol 1976;14:33-71.
38. Liu R, Gan L, Yang X, Xu H. Chitosan as a condensing agent induces high gene transfection efficiency and low cytotoxicity of liposome. J Biosci Bioeng 2011;111:98-103.
39. Liu J, Boonkaew B, Arora J, et al. Comparison of sorafenib-loaded poly (lactic/glycolic) acid and DPPC liposome nanoparticles in the in vitro treatment of renal cell carcinoma. J Pharm Sci 2015;104:1187-96.
40. Yamada Y, Munechika R, Kawamura E, Sakurai Y, Sato Y, Harashima H. Mitochondrial delivery of doxorubicin using MITO-porter kills drug-resistant renal cancer cells via mitochondrial toxicity. J Pharm Sci 2017;106:2428-37.
41. Yu Z, Wang Y, Xu D, et al. G250 antigen-targeting drug-loaded nanobubbles combined with ultrasound targeted nanobubble destruction: a potential novel treatment for renal cell carcinoma. Int J Nanomed 2020;15:81-95.
43. Wang J, Potocny AM, Rosenthal J, Day ES. Gold nanoshell-linear tetrapyrrole conjugates for near infrared-activated dual photodynamic and photothermal therapies. ACS Omega 2020;5:926-40.
44. Seeley EH, Oppenheimer SR, Mi D, Chaurand P, Caprioli RM. Enhancement of protein sensitivity for MALDI imaging mass spectrometry after chemical treatment of tissue sections. J Am Soc Mass Spectrom 2008;19:1069-77.
45. Hájek R, Lísa M, Khalikova M, et al. HILIC/ESI-MS determination of gangliosides and other polar lipid classes in renal cell carcinoma and surrounding normal tissues. Anal Bioanal Chem 2018;410:6585-94.
46. Nizioł J, Rode W, Laskowska B, Ruman T. Novel monoisotopic 109AgNPET for laser desorption/ionization mass spectrometry. Anal Chem 2013;85:1926-31.
47. Nizioł J, Ossoliński K, Tripet BP, Copié V, Arendowski A, Ruman T. Nuclear magnetic resonance and surface-assisted laser desorption/ionization mass spectrometry-based metabolome profiling of urine samples from kidney cancer patients. J Pharm Biomed Anal 2021;193:113752.
48. Fujishima A, Honda K. Electrochemical photolysis of water at a semiconductor electrode. Nature 1972;238:37-8.
49. Yang C, Zhu Y, Li D, et al. Red phosphorus decorated TiO2 nanorod mediated photodynamic and photothermal therapy for renal cell carcinoma. Small 2021;17:e2101837.
50. Soprano E, Polo E, Pelaz B, Del Pino P. Biomimetic cell-derived nanocarriers in cancer research. J Nanobiotechnol 2022;20:538.
51. von Rundstedt FC, Scovell JM, Agrawal S, Zaneveld J, Link RE. Utility of patient-specific silicone renal models for planning and rehearsal of complex tumour resections prior to robot-assisted laparoscopic partial nephrectomy. BJU Int 2017;119:598-604.
52. Li H, Yang C, Wang K, et al. Grading and surgical treatment of renal cell carcinoma combined with inferior vena cava carcinoma thrombosis. J Min Invas Urol 2022;11:342-6.
53. Ciancio G. Inferior Vena cava reconstruction using a ringed polytetrafluoroethylene interposition graft and inferior vena cava filter placement following resection of renal cell carcinoma with a tumor thrombus directly infiltrating the inferior vena cava. Vasc Endovascular Surg 2022;56:5-10.
54. Gradilone A, Iacovelli R, Cortesi E, et al. Circulating tumor cells and “suspicious objects” evaluated through CellSearch® in metastatic renal cell carcinoma. Anticancer Res 2011;31:4219-21.
55. Zhang Y, Rana A, Stratton Y, Czyzyk-Krzeska MF, Esfandiari L. Sequence-specific detection of MicroRNAs related to clear cell renal cell carcinoma at fM concentration by an electroosmotically driven nanopore-based device. Anal Chem 2017;89:9201-8.
56. Arendowski A, Ossoliński K, Ossolińska A, Ossoliński T, Nizioł J, Ruman T. Serum and urine analysis with gold nanoparticle-assisted laser desorption/ionization mass spectrometry for renal cell carcinoma metabolic biomarkers discovery. Adv Med Sci 2021;66:326-35.
57. Nizioł J, Sunner J, Beech I, et al. Localization of metabolites of human kidney tissue with infrared laser-based selected reaction monitoring mass spectrometry imaging and silver-109 nanoparticle-based surface assisted laser desorption/ionization mass spectrometry imaging. Anal Chem 2020;92:4251-8.
58. Zhang L, Yu C, Gao R, et al. An impedimetric biosensor for the diagnosis of renal cell carcinoma based on the interaction between 3-aminophenyl boronic acid and sialic acid. Biosens Bioelectron 2017;92:434-41.
59. Niciński K, Krajczewski J, Kudelski A, et al. Detection of circulating tumor cells in blood by shell-isolated nanoparticle - enhanced Raman spectroscopy (SHINERS) in microfluidic device. Sci Rep 2019;9:9267.
60. Arendowski A, Nizioł J, Ossoliński K, et al. Laser desorption/ionization MS imaging of cancer kidney tissue on silver nanoparticle-enhanced target. Bioanalysis 2018;10:83-94.
61. Renner AM, Derichsweiler C, Ilyas S, Gessner I, Fries JWU, Mathur S. High efficiency capture of biomarker miRNA15a for noninvasive diagnosis of malignant kidney tumors. Biomater Sci 2022;10:1113-22.
62. Zhang X, Liu R, Yuan Q, et al. The precise diagnosis of cancer invasion/metastasis via 2D laser ablation mass mapping of metalloproteinase in primary cancer tissue. ACS Nano 2018;12:11139-51.
63. Himbert D, Zeuschner P, Ayoubian H, Heinzelmann J, Stöckle M, Junker K. Characterization of CD147, CA9, and CD70 as Tumor-specific markers on extracellular vesicles in clear cell renal cell carcinoma. Diagnostics 2020;10:1034.
64. Lu C, Li J, Xu K, et al. Fabrication of mAb G250-SPIO molecular magnetic resonance imaging nanoprobe for the specific detection of renal cell carcinoma in vitro. PLoS One 2014;9:e101898.
65. Guimaraes AR, Tabatabei S, Dahl D, McDougal WS, Weissleder R, Harisinghani MG. Pilot study evaluating use of lymphotrophic nanoparticle-enhanced magnetic resonance imaging for assessing lymph nodes in renal cell cancer. Urology 2008;71:708-12.
66. Kuusk T, De Bruijn R, Brouwer OR, et al. Lymphatic drainage from renal tumors in vivo: a prospective sentinel node study using SPECT/CT imaging. J Urol 2018;199:1426-32.
67. Li J, Wu C, Hou P, Zhang M, Xu K. One-pot preparation of hydrophilic manganese oxide nanoparticles as T1 nano-contrast agent for molecular magnetic resonance imaging of renal carcinoma in vitro and in vivo. Biosens Bioelectron 2018;102:1-8.
68. Zhu L, Wang L, Liu Y, Xu D, Fang K, Guo Y. CAIX aptamer-functionalized targeted nanobubbles for ultrasound molecular imaging of various tumors. Int J Nanomed 2018;13:6481-95.
69. Funasaki S, Mehanna S, Ma W, et al. Targeting chemoresistance in Xp11.2 translocation renal cell carcinoma using a novel polyamide-chlorambucil conjugate. Cancer Sci 2022;113:2352-67.
70. Lee HW, Seo HS, Yeom SY, et al. Cabozantinib-loaded PLGA nanoparticles: a potential adjuvant strategy for surgically resected high-risk non-metastatic renal cell carcinoma. Int J Mol Sci 2022;23:12634.
71. Gao X, Jiang P, Zhang Q, et al. Peglated-H1/pHGFK1 nanoparticles enhance anti-tumor effects of sorafenib by inhibition of drug-induced autophagy and stemness in renal cell carcinoma. J Exp Clin Cancer Res 2019;38:362.
72. Fujii H, Shin-Ya M, Takeda S, et al. Cycloamylose-nanogel drug delivery system-mediated intratumor silencing of the vascular endothelial growth factor regulates neovascularization in tumor microenvironment. Cancer Sci 2014;105:1616-25.
73. Yongvongsoontorn N, Chung JE, Gao SJ, et al. Carrier-enhanced anticancer efficacy of sunitinib-loaded green tea-based micellar nanocomplex beyond tumor-targeted delivery. ACS Nano 2019;13:7591-602.
74. Takke A, Shende P. Magnetic-core-based silibinin nanopolymeric carriers for the treatment of renal cell cancer. Life Sci 2021;275:119377.
75. Keefe SM, Hoffman-Censits J, Cohen RB, et al. Efficacy of the nanoparticle-drug conjugate CRLX101 in combination with bevacizumab in metastatic renal cell carcinoma: results of an investigator-initiated phase I-IIa clinical trial. Ann Oncol 2016;27:1579-85.
76. Racaniello GF, Laquintana V, Vergnaud J, et al. Development of purified glycogen derivatives as siRNA nanovectors. Int J Pharm 2021;608:121128.
77. Takara K, Hatakeyama H, Kibria G, Ohga N, Hida K, Harashima H. Size-controlled, dual-ligand modified liposomes that target the tumor vasculature show promise for use in drug-resistant cancer therapy. J Control Release 2012;162:225-32.
78. Kibria G, Hatakeyama H, Ohga N, Hida K, Harashima H. The effect of liposomal size on the targeted delivery of doxorubicin to Integrin αvβ3-expressing tumor endothelial cells. Biomaterials 2013;34:5617-27.
79. Takai T, Tsujino T, Yoshikawa Y, et al. Synthetic miR-143 exhibited an anti-cancer effect via the downregulation of K-RAS networks of renal cell cancer cells in vitro and in vivo. Mol Ther 2019;27:1017-27.
80. Chai D, Liu N, Li H, et al. H1/pAIM2 nanoparticles exert anti-tumour effects that is associated with the inflammasome activation in renal carcinoma. J Cell Mol Med 2018;22:5670-81.
81. Ni W, Li Y, Liang L, et al. Tumor microenvironment-responsive nanodrug for clear-cell renal cell carcinoma therapy via triggering waterfall-like cascade ferroptosis. J Biomed Nanotechnol 2022;18:327-42.
82. Zhai X, Yuan S, Yang X, et al. Chitosan oligosaccharides induce apoptosis in human renal carcinoma via reactive-oxygen-species-dependent endoplasmic reticulum stress. J Agric Food Chem 2019;67:1691-701.
83. Tannir NM, Papadopoulos KP, Wong DJ, et al. Pegilodecakin as monotherapy or in combination with anti-PD-1 or tyrosine kinase inhibitor in heavily pretreated patients with advanced renal cell carcinoma: final results of cohorts A, G, H and I of IVY phase I study. Int J Cancer 2021;149:403-8.
84. Cai B, Hou M, Zhang S, et al. Dual targeting of endoplasmic reticulum by redox-deubiquitination regulation for cancer therapy. Int J Nanomed 2021;16:5193-209.
85. Kannadorai RK, Chiew GGY, Luo KQ, Liu Q. Dual functions of gold nanorods as photothermal agent and autofluorescence enhancer to track cell death during plasmonic photothermal therapy. Cancer Lett 2015;357:152-9.
86. Bex A, Vermeeren L, de Windt G, Prevoo W, Horenblas S, Olmos RA. Feasibility of sentinel node detection in renal cell carcinoma: a pilot study. Eur J Nucl Med Mol Imaging 2010;37:1117-23.
87. Lang Y, Tian X, Dong HY, et al. Black phosphorus quantum dots enhance the radiosensitivity of human renal cell carcinoma cells through inhibition of DNA-PKcs kinase. Cells 2022;11:1651.
88. Chen J, Ren F, Cao W, et al. Photothermal therapy enhance the anti-mitochondrial metabolism effect of lonidamine to renal cell carcinoma in homologous-targeted nanosystem. Nanomedicine 2021;34:102370.
89. Yamamoto S, Kato A, Sakurai Y, Hada T, Harashima H. Modality of tumor endothelial VEGFR2 silencing-mediated improvement in intratumoral distribution of lipid nanoparticles. J Control Release 2017;251:1-10.
90. Whiteside TL. Tumor-derived exosomes and their role in cancer progression. Adv Clin Chem 2016;74:103-41.
91. Mao W, Wang K, Wu Z, Xu B, Chen M. Current status of research on exosomes in general, and for the diagnosis and treatment of kidney cancer in particular. J Exp Clin Cancer Res 2021;40:305.
92. Kahlert C, Kalluri R. Exosomes in tumor microenvironment influence cancer progression and metastasis. J Mol Med 2013;91:431-7.
93. Mathieu M, Martin-Jaular L, Lavieu G, Théry C. Specificities of secretion and uptake of exosomes and other extracellular vesicles for cell-to-cell communication. Nat Cell Biol 2019;21:9-17.
94. Kalluri R, LeBleu VS. The biology, function, and biomedical applications of exosomes. Science 2020;367:eaau6977.
95. Liu Y, Wu W, Cai C, Zhang H, Shen H, Han Y. Patient-derived xenograft models in cancer therapy: technologies and applications. Signal Transduct Target Ther 2023;8:160.
96. Voss MH, Hussain A, Vogelzang N, et al. A randomized phase II trial of CRLX101 in combination with bevacizumab versus standard of care in patients with advanced renal cell carcinoma. Ann Oncol 2017;28:2754-60.
97. Boorjian SA, Milowsky MI, Kaplan J, et al. Phase 1/2 clinical trial of interferon alpha2b and weekly liposome-encapsulated all-trans retinoic acid in patients with advanced renal cell carcinoma. J Immunother 2007;30:655-62.
98. Johannsen M, Spitaleri G, Curigliano G, et al. The tumour-targeting human L19-IL2 immunocytokine: preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma. Eur J Cancer 2010;46:2926-35.
99. Lasorsa F, Rutigliano M, Milella M, et al. Cancer stem cells in renal cell carcinoma: origins and biomarkers. Int J Mol Sci 2023;24:13179.
100. Xiong Z, Xiao W, Bao L, et al. Tumor cell “slimming” regulates tumor progression through PLCL1/UCP1-mediated lipid browning. Adv Sci 2019;6:1801862.
101. Xiong Z, Xiong W, Xiao W, et al. NNT-induced tumor cell “slimming” reverses the pro-carcinogenesis effect of HIF2a in tumors. Clin Transl Med 2021;11:e264.
